Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 12, 2003, Pages 2025-2027

  Urbaniak, Michael D ^a   Frost, Lisa M ^a   Bingham, John P ^b   Kelland, Lloyd R ^c   Hartley, John A ^b   Woolfson, Derek N ^a   Caddick, Stephen ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYNAPHTHOATE; CARBONYL DERIVATIVE; CHEMICAL COMPOUND; CYCLOPENTANONE DERIVATIVE; HYDROXYL GROUP; UNCLASSIFIED DRUG; ZINOSTATIN CHROMOPHORE;

ARTICLE; CYTOTOXICITY; DIHYDROXYLATION; DRUG ACTIVITY; DRUG SYNTHESIS; EVALUATION; LEUKEMIA CELL LINE; NONHUMAN; SYNTHESIS; TUMOR CELL LINE;

EID: 0037763901     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00328-7     Document Type: Article

References (11)

1. Ishida N., Miyuzaki K., Kumagai K., Rikimaru M. J. Antibiot. 18:1965;68.
2. Maeda, H.; Edo, K.; Ishida, N. In Neocarzinostatin: The Past, Present and Future of an Anticancer Drug; Springer-Verlag: Tokoyo, 1997, p 287.
3. Myers A.G. Tetrahedron Lett. 28:1987;4493.
4. Gao X., Stassinopoulos A., Rice J.S., Goldberg I.H. Biochemistry. 34:1995;40.
5. Hodgkinson T.J., Kelland L.R., Shipman M., Suzenet F. Bioorg. Med. Chem. Lett. 10:2000;239.
6. Caddick S., Khan S. J. Chem. Soc., Chem. Comm. 19:1995;1971.
7. Caddick S., Khan S., Frost L.M., Smith N.J., Cheung S., Pairaudeau G. Tetrahedron. 56:2000;8953.
8. Caddick S., Cheung S., Doyle V.E., Frost L.M., Soscia M.G., Delisser V.M., Williams M.R., Etheridge Z.C., Khan S., Hitchcock P.B., Pairaudeu G., Vile S. Tetrahedron. 57:2001;6295.
9. Urbaniak M.D., Muskett F.W., Finucane M.D., Caddick S., Woolfson D.N. Biochemistry. 41:2002;11731.
10. 4 cells/mL) were aliquoted into 96-well microtitre plate and incubated for 1 h with the test compound (100 μM to 30 nM). After washing, the cells were incubated for a further four days before the number of viable cells was counted using the MTT assay. For a description of the MTT assay see: Alloy M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Cancer Res. 48:1988;589.
11. 4 cells/mL) and allowed to attach overnight. Test compounds (100 μM to 2.5 nM) were incubated with the cells for 96 h, then the number of cells was counted using the Sulforhodamine B (SRB) assay. For a description of the SRB assay see: Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J., Bokesh H., Kennedy S., Boyd M.R. J. Nat. Cancer Inst. 82:1990;1107.